SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen depri
SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen deprivation therapy — with enzalutamide — with a PSA decline of at least 30 per cent. Heather H Cheng MD PhD, who is a Senior Reseach Fellow at the Fred Hutchinson Cancer Research Center in Seattle, Washington, presented her results at a poster session of the 2014 ASCO Genitourinary Cancers Symposium.
CONTACT:
Heather H Cheng MD PhD
Senior Reseach Fellow
Fred Hutchinson Cancer Research Center
Seattle, Washington 98109
SOURCE:
2014 ASCO Genitourinary Symposium, San Francisco
Abstract 18
“The effect of prior abiraterone use on the activity of enzalutamide in men with mCRPC”
ABSTRACT LINK:
http://meetinglibrary.asco.org/content/124184-142